GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aarti Drugs Ltd

Aarti Drugs Board Meeting to Approve Q2 & H1 FY27 Financial Results

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 27 Oct 2026, 08:55 PM IST  ·  BSE ID: ca88f6e8-aee7-49ac-8b5b-66ddba3cf8fe
View Original BSE Filing (PDF)
💡
In Simple Terms
Aarti Drugs will hold a board meeting on November 3, 2026, to approve its financial results for Q2 and H1 FY27.
🤖 AI Summary
  • Aarti Drugs Ltd. Board Meeting scheduled for Tuesday, November 3, 2026.
  • Agenda includes considering and approving Audited Financial Results for Quarter and Half Year ended September 30, 2026.
  • Trading window remains closed until 48 hours post financial results declaration.
  • Intimation pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this intimation.
👤
Who Is Affected
Shareholders are informed of the upcoming board meeting, indicating that the half-yearly financial performance details will be released soon. All shareholders are equally affected.
🔍
Management Signal
The management is adhering to regulatory requirements by intimating the board meeting for financial results approval and maintaining the trading window closure.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Declaration of Audited Financial Results for Q2 and H1 FY27.
Company Secretary's statement on trading window re-opening date.
Analysis of revenue and profit figures in the upcoming results.
LOW RISK This is a routine regulatory filing announcing a scheduled board meeting, carrying minimal inherent risk.
💡 Investor Takeaway
Aarti Drugs Ltd. has scheduled a Board Meeting for November 3, 2026, to consider and approve its Audited Financial Results for the quarter and half year ended September 30, 2026. This is a procedural announcement ahead of the actual results disclosure.
📅 Company Track Record
Aarti Drugs previously reported Q1 FY27 consolidated revenue of Rs. 70,278 lakhs and a consolidated profit of Rs. 5,013 lakhs for the quarter ended June 30, 2026. The company's Q1 FY27 consolidated revenue was up 19% YoY, while PAT was down 7% YoY.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
When is Aarti Drugs Ltd.'s next Board Meeting scheduled?
Aarti Drugs Ltd.'s next Board Meeting is scheduled for Tuesday, November 3, 2026.
What is the primary agenda for the Aarti Drugs Ltd. Board Meeting on November 3, 2026?
The primary agenda for the Board Meeting on November 3, 2026, is to consider, approve, and take on record the Audited Financial Results for the Quarter and Half Year ended September 30, 2026.
When will the trading window for Aarti Drugs Ltd. re-open?
The trading window for Aarti Drugs Ltd. shall remain closed until the expiry of 48 hours after the declaration of the said Financial Results.
Which SEBI regulation is this Aarti Drugs Ltd. intimation related to?
This Aarti Drugs Ltd. intimation is made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.